As a possible route for invasion of the CNS, circulating poliovirus (PV) in the blood is believed to traverse the blood-brain barrier (BBB), resulting in paralytic poliomyelitis. However, the underlying mechanism is poorly understood. In this study, we demonstrated that mouse transferrin receptor 1 (mTfR1) is responsible for PV attachment to the cell surface, allowing invasion into the CNS via the BBB. PV interacts with the apical domain of mTfR1 on mouse brain capillary endothelial cells (MBEC4) in a dose-dependent manner via its capsid protein (VP1). We found that F-G, G-H, and H-I loops in VP1 are important for this binding. 
of cells; however, PV replication is restricted by host immune activities (e.g. IFN-␣/␤) (4 -6) . Although wild-type mice are not sensitive to PV (7), hPVR-expressing transgenic (Tg) mice were susceptible to PV via intravenous and intramuscular routes but not the oral route (7) (8) (9) (10) (11) (12) . Further, an IFN-␣/␤-deficient hPVR-Tg mouse was found to be susceptible to PV via the oral route (13) .
As a possible route for invasion of the CNS, PV enters the CNS via axonal transport through the skeletal muscle in an hPVR-dependent manner (14) . Endocytic vesicles at the synapse take up intact PV, which is passively transported to the CNS. Interestingly, PV has been shown to invade the CNS via hPVR-independent axonal transport in hPVR-Tg and non-Tg mice (15) , indicating that other unidentified pathways for PV transport may be present. Furthermore, we previously showed that PV promptly invades the CNS from the blood in non-Tg mice, which supports this speculation (16) . In that study, intravenously injected PV permeated the brain as fast as cationized rat serum albumin, which is BBB-permeable (16) .Therefore, PV is thought to efficiently permeate the CNS by overcoming the BBB.
The BBB is composed of a multilayer barrier composed of vascular endothelial cells with tight junctions filling the gaps between cells (17) . Although the BBB was discovered over a century ago, its transport mechanisms are not fully understood. It restricts transport of substances between the CNS and blood by maintaining a strictly regulated microenvironment for high integrity neuronal response in the CNS (18, 19) . Certain substances are permitted transmission via the BBB from the bloodstream to the brain, facilitated by specific transporters on the cell membrane (e.g. glucose, amino acids, transferrin, and insulin) (20 -25) . For example, transferrin is known to facilitate iron transport from the blood to the cells (26) . Iron uptake increases transferrin affinity for the transferrin receptor on the cell membrane. The iron-transferrin complex is transported into the cells by receptor-mediated transcytosis, followed by the release of iron into the cytoplasm; transferrin then goes back to the outer cell membrane for recycling. This mechanism is sometimes exploited by viruses for entry during infection (27) (28) (29) (30) (31) .
Given that transferrin receptor is a transporter in brain capillary endothelial cells and can be used as an entry receptor for several viral infections, we hypothesized that PV similarly invades the CNS via the BBB by using transferrin receptor as a vehicle. We examined this possibility in this study and demonstrated the interaction of PV with mouse transferrin receptor 1 (mTfR1) in vitro. Furthermore, we identified that VP1, a PV capsid protein, is responsible for the physical interaction between PV and mTfR1. Co-incubation with transferrin or knockdown of mTfR1 resulted in delayed PV transcytosis via the brain capillary endothelial cells in the BBB in vitro model. We identified the domain of VP1 responsible for attachment to mTfR1 and permeation of the brain capillary endothelial cells. In summary, we provide convincing evidence to support the direct involvement of mTfR1 in PV permeation into the CNS via BBB by using an in vitro model.
Experimental Procedures
Cell Culture-Mouse brain capillary endothelial cells (MBEC4) isolated from BALB/c mice brain cortices and immortalized by SV40 transformation were maintained (32) in DMEM containing 10% fetal calf serum at 37°C and 5% CO 2 . African green monkey kidney (AGMK) cells were grown in DMEM supplemented with 5% newborn calf serum.
Plasmid Construction-The pCold-GST-6His vector was generated by inserting GST fragment (0.3 kb at DraIII-BamHI sites) in pCold-I vector (Takara Bio Ltd., Shiga, Japan), then a His 6 fragment was inserted between the XhoI and NotI restriction sites (33) . To generate pCold-GST-6His-VP1, -VP2, and -VP3 vectors, all the coding fragments of capsid proteins (VP1, VP2, and VP3) were amplified by PCR, and these fragments were introduced at the BamHI/XhoI site in the pCold-GST6His vector. The pCold-GST-Venus-6His-VP1 and each VP1 loop peptide (cDNA) were constructed as follows. To generate the pCold-GST-Venus-6His-empty vector, the PCR fragment of 0.7-kb Venus cDNA was inserted into the BamHI/XhoI site in the pCold-GST-6His vector. The linker sequence (SRG[SGGGG] 2 SSG) was introduced at XhoI sites in the pCold-GST-Venus-6His vector to generate pCold-GST-Venus-L-6His. The whole cDNA or peptide sequences of VP1 were inserted after linker sequence at the EcoRI/XhoI site in pCold-GST-Venus-L-6His. FLAG-mTfR1 and a series of its deletion mutants (FLAG-mTfR1-609, -388 -186, PD2, and AD) were inserted into pTNT vector (Promega Corp., Madison, WI). FLAG-mTfR1 fragment was inserted into a pcDNA3.1-FLAG vector (34) to generate pcDNA3.1-FLAG-mTfR1. Short hairpin RNAs were derived from mouse U6 promoter (mU6) on shRNA expressing retrovirus vector, pSSSP (35) . This vector is self-inactivating and contains SV40 promoter-puromycin cassette. The mU6-driven shRNA cassette is introduced in the deleted U3 region of 3Ј long terminal repeat. The target sequence of short hairpin RNA used in this study are listed below: shmTfR1, 5Ј-GAACCAGTTGTAAGAAC-AAT-G-3Ј, and shLacZ (control), 5Ј-GCAGTTATCTGGA-AGATCAGG-3Ј.
Antibodies-The following antibodies were used in this study: rabbit anti-PV1/Mahoney hyperimmune serum was prepared by immunizing rabbits with purified PV1/Mahoney, antiFlag (Wako Pure Chemical Industries Ltd., Osaka, Japan), antitransferrin receptor (Zymed Laboratories Inc.. Inc., San Francisco, CA), and anti-␤-actin (013-24553; Wako LTD., Osaka, Japan). In Western blotting experiments, band images were analyzed using the LAS 4000 UV mini system (Lifescience Technologies).
In Vitro Binding Experiments-GST fusion proteins were expressed in Escherichia coli Rosetta 2 (Novagen, Madison, WI) via incubation of the cells with 0.1 mM isopropyl 1-thio-␤-Dgalactopyranoside overnight at 15°C and then suspended in E. coli using His tag binding/wash buffer (20 mM Tris-HCl, pH 8.0, 600 mM NaCl, 1 mM MgCl 2 , 10% glycerol, 0.1% Nonidet P-40, 20 mM imidazole, and phosphatase inhibitors). E. coli was sonicated on ice using ELESTAIN035SD (ELECON Science. Corp, Chiba, Japan). Purification of GST-His-tagged proteins was performed sequentially using Profinity IMAC nickelcharged resin (Bio-Rad) and glutathione-Sepharose 4B (GE Healthcare). The target proteins were eluted from these columns with His tag elution buffer (20 mM Tris-HCl, pH 8.0, 600 mM NaCl, 1 mM MgCl 2 , 10% glycerol, 0.1% Nonidet P-40, 250 mM imidazole, and protease inhibitors) and GST elution buffer (100 mM Tris-HCl, pH 8.0, 12 mM NaCl, 20 mM glutathione, and protease inhibitors), respectively. [
35 S]Methionine-labeled fulllength mTfR1 or its derivative constructs were translated using a reticulocyte lysate system in vitro (Promega Corporation, Madison, WI), and incubated with PV particles or respective GST fusion proteins at 4°C on a rotating platform for 2 h. The precipitated materials were washed for five times with TNE buffer (10 mM Tris-HCl, pH 7.8, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, and protease inhibitors) and analyzed by SDS-PAGE followed by autoradiography.
Immunoprecipitation Assay-Immunoprecipitation assays were performed as previously described (34) . Briefly, cells were lysed with TNE buffer (10 mM Tris-HCl, pH 7.8, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, and protease inhibitors), and cell lysates were incubated overnight on a rotating platform at 4°C with respective antibodies (5 g each), which were previously bound to Dynabeads Protein G (Dynal, Oslo, Norway). After washing, precipitates were purified, subjected to SDS-PAGE, and analyzed by Western blotting or autoradiography.
PV Purification and Fluorescent Label of PV-PV was purified by a protocol described previously (36) . HeLa cells were infected with Mahoney virus at a multiplicity of infection of 10. The cells were harvested at 8 h postinfection, and the virus was purified from cytoplasmic extracts of the infected cells by using DEAE-Sepharose CL-6B, followed by sucrose density gradient and CsCl equilibrium centrifugation. Purified virus was desalted by gel filtration on a PD-10 column equilibrated with PBS(Ϫ). The PV concentration was determined by measuring the absorbance at 260 nm; 1.0 optical density unit was regarded as equivalent to 9.4 ϫ 10 12 virions. Virus labeling was based on a protocol, which was described previously (13, 37) . Briefly, PV was labeled with Alexa Fluor-succinimidyl ester according to the manufacturer's instructions (Life Technologies). The labeled virus was purified on NAP5 columns (GE Healthcare), dialyzed against PBS(Ϫ) without loss of the specific infectivity.
Titration of Virus Infectivity-The numbers of plaque-forming unit in AGMK cells were determined by the plaque assay. For the measurement of plaque-forming unit, AGMK cells on 6-cm dishes were inoculated with the viral suspension and then incubated at 37°C for 2-5 days for the observation of plaques.
Transwell in vitro blood brain barrier (BBB) permeation assay-Alexa 488-conjugated mouse transferrin was purchased from Jackson ImmunoResearch Laboratories. FITC-labeled dextran (2,000 K) was purchased from Sigma-Aldrich. Mouse brain capillary endothelial cells (MBEC4) were seeded (5 ϫ 10 4 cells/well) into collagen-coated 24-well Transwell plates (#3496; Corning) and cultured for 48 h at 37°C under 5% CO 2 (7) . In vitro monolayer integrity was evaluated as trans-endothelial electrical resistance (TEER) using a Millicell ERS voltohmmeter (Millipore, Bedford, MA). The average TEER value of the cellular monolayer was 50 Ϯ 10 ⍀⅐cm 2 after background subtraction of the TEER value of a cell empty (blank) control well. Preparing 126.55 g/ml purified PV particle, PV permeation was calculated as clearance volume in each time point as below: clearance volume (l) ϭ permeated apical side fluorescent intensity (g)/input PV fluorescent intensity volume (g/l).
FACS Analysis-MBEC4 cells were assessed by single-color flow cytometric analysis. The following antibodies were used for the flow cytometric analysis: FITC anti-mouse CD71/TfR1 antibody (113805) (BioLegend, San Diego, CA). Dead cells were excluded with the propidium iodide staining (Sigma-Aldrich). Samples were analyzed on iCyte flow cytometer (Sony Biotechnology Inc., San Jose, CA).
Statistical Analyses-We performed t test. All statistical tests were two-sided. We considered p values less than 0.05 to be statistically significant.
Results

PV Interacts with TfR1 on Mouse Brain Capillary Endothelial
Cells-To elucidate the interaction between PV particles and the transferrin receptor, we generated mouse brain capillary endothelial cell line (MBEC4) expressing FLAG-mTfR1. Because it is known that in PV-sensitive cells, the association between PV capsid and hPVR promptly leads to PV capsid conformational change followed by cell entry, we used PV-insensitive mouse cell lines to avoid this conformational change. We conducted immunoprecipitation using anti-PV antibody on total lysate obtained from FLAG-mTfR1-MBEC4 cells exposed to PV for 1 h, followed by blotting with anti-FLAG antibody (Fig. 1A) . FLAG-mTfR1 was clearly detected by Western blotting using an antibody against FLAG peptide. Next, we evaluated the interaction between PV and endogenous TfR1 on MBEC4 cells. The MBEC4 cells were then exposed to various concentrations of PV for 1 h, following which the supernatant was discarded, and the whole cell extract was collected. Following immunoprecipitation using anti-PV antibody, endogenous mTfR1 was detected by Western blot using anti-mTfR1 antibody in accordance with the PV dose (Fig. 1B) . These results suggested that PV interacts with mTfR1 in vitro.
We speculated that if PV requires mTfR1 for cell permeation, PV might compete against transferrin during transport into cells. To examine this possibility, we assessed FITC-labeled transferrin transport into MBEC4 cells in the presence of pretreated PV or dextran. Because dextran is known to permeate into arterial endothelial cells (39) through the intercellular gap (40) by virtue of its size (molecular mass, Ͼ15 kDa), dextran (molecular mass, 2 ϫ 10 3 kDa) was used as a control for a different pathway of permeation. It was presumably of a size similar to that of the PV particle, which is ϳ8.6 ϫ 10 3 kDa (41, 42) . Co-treatment with purified PV effectively inhibited FITC-labeled transferrin transport into MBEC4 cells (Fig. 1C) . However, an excess amount of dextran as compared with that of PV showed no effect, even with increasing doses (Fig. 1D) . This observation confirmed the interaction between PV and mTfR1 in vitro.
PV Interacts with mTfR1 through the Ectodomain-To identify the domains of PV and mTfR1 that are responsible for their 
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FEBRUARY 5, 2016 • VOLUME 291 • NUMBER 6 interaction, we identified the region of mTfR1 necessary for PV interaction. Because mTfR1 contains three identical extracellular domains ( Fig. 2A) , we divided mTfR1 into four regions and generated in vitro translated 35 S-labeled, FLAG-fused, and fulllength mTfR1, as well as three derivative mTfR1 truncations using reticulocyte lysate (Fig. 2B ). Subsequently, we tested their interaction with purified PV. The results showed that PV particles directly interact with full-length mTfR1 (Fig. 2C) . Each truncated mTfR1 (mTfR1-609 and -388) also interacted with PV particles, except for the mTfR1-186 construct (Fig. 2C) . According to the predicted structure of TfR1, the helical domain of TfR1 is folded into its homodimeric receptor (26) . This hinders the natural interaction between PV and the helical domain. Together, these results indicated that the PV particle may interact with the apical domain and/or secondary part of protease-like domain of mTfR1.
PV Efficiently Interacts with the Apical Domain of mTfR1-We further identified the mTfR1 domain that associates with the PV particle. We constructed and generated in vitro translated, 35 S-labeled apical domain (AD) and second region of protease-like domain (PD2) of mTfR1 (Fig. 2D) . The result showed that both mTfR1-AD and -PD2 are efficiently precipitated with PV particle (Fig. 2E) , although the background signal was slightly higher in the precipitation using mTfR1-PD2. Together with the result shown in Fig. 2C , this result implied that the apical domain of mTfR1 is important for PV association. Given that the outer side of the PV capsid is composed of three polypeptides (VP1, VP2, and VP3), these proteins are candidates for interaction with mTfR1. To identify the PV capsid protein responsible for mTfR1 association, we constructed GST fusion VP1, VP2, and VP3 plasmids and generated the corresponding recombinant proteins in E. coli. We then conducted GST pulldown assays using purified GST alone, GST-VP1, GST-VP2, and GST-VP3 and in vitro translated, 35 S-labeled full-length mTfR1, as well as the three truncated proteins (Fig. 3A) . VP1 clearly bound to all mTfR1 constructs, except for the mTfR1-186 mutant (Fig. 3B ). VP2 and VP3 showed weak or no binding to any of the truncated mutants, although they bound to fulllength mTfR1. This result is possibly due to conformational changes by truncation. Together, these results suggested that VP1 is the capsid protein with the highest affinity for mTfR1.
F-G, G-H, and H-I Loops on VP1 Are Responsible for Interaction with the Apical Domain of mTfR1-VP1
contains eight large ␤-sheet structures, and these antiparallel strands are compactly packed into the PV particle, similar to VP2 and VP3 (Fig.  4A) (43) . VP1 contains seven loop domains that are considered as the outer exposed domains of the VP1 structure. To identify the VP1 loop responsible for interaction with the AD or PD2 domain of mTfR1, we constructed seven GST-Venus-fused , and VP3 proteins were purified from E. coli lysates and GST pulldown assay with in vitro translated AD and PD2 of mTfR1. GST pulldown materials were stained by Coomassie Blue. An asterisk indicates the nonspecific precipitated bands derived from reticulocyte lysates (A). The precipitate of the GST pulldown assay was exposed to autoradiography after SDS-gel electrophoresis (B).
proteins, each containing VP1 loops under Venus protein ( Fig.  4B and Table 1 ). We performed GST pulldown assays using these purified GST-Venus fusion proteins and in vitro translated AD or PD2 of mTfR1 (Fig. 4C) . F-G, G-H, and H-I loops showed GST-Venus-fused protein clearly bound to the AD of mTfR1. GST-Venus-fused protein containing F-G loops was the only protein that interacted with PD2 of mTfR1 (Fig. 4C) . These results showed that F-G, G-H, and H-I loops of VP1 are the domains mainly responsible for the interaction between PV and mTfR1.
PV Permeates Mouse Brain Capillary Endothelial Cells and Competes against Transferrin for Transport into Cells-We
determined whether PV has the ability to permeate brain capillary endothelial cells in vitro. We performed cell permeation assay and quantified the cell-permeating ratio into MBEC4 cells using purified GST-Venus-VP1 and the 7 GST-Venus-VP1-loop proteins (Fig. 4B) . The Venus fusion proteins were incubated with MBEC4 cells for 24 h, followed by preparation of cell lysate and measurement of fluorescence intensity of the permeated protein. As shown in Fig. 4D , full-length VP1 and B-C loops of VP1 connected with GST-Venus proteins exhibited marginal permeation into MBEC4 cells compared with control fusion protein. C-D, D-E, and E-F loops of VP1 connected with GST-Venus protein showed Ͼ2-fold permeable efficiency into MBEC4 cells, whereas F-G, G-H, and H-I loops of VP1, responsible for mTfR1 attachment, showed poor permeation into MBEC4 cells. These results suggest that the VP1 loops responsible for attachment to mTfR1 and permeation into MBEC4 cells are indeed different.
Knockdown of Transferrin Receptor Prevents PV Transmission in the in Vitro BBB Model-Our group previously observed that circulating PV promptly invaded the brain from the blood via the BBB in a non-hPVR-Tg mouse model (16) . To confirm whether PV uses the transferrin receptor to invade the CNS, we conducted Transwell BBB in vitro model assay using MBEC4 cells (38) , wherein MBEC4 cells were confluently seeded on a microporous membrane in the upper chamber of the Transwell. MBEC4 cells were exposed to fluorescein-labeled PV with or without transferrin, and then fluorescence intensity of the medium collected from the lower chamber was assessed to monitor PV that had permeated the MBEC4 cells (Fig. 5A) . Because dextran is known to permeate into arterial endothelial cells (39) through the intercellular gap (40) by virtue of its size (molecular mass, Ͼ15 kDa), we used dextran as the permeation control. To validate the Transwell BBB in vitro model assay system, we first compared the permeation ratio of FITC-labeled transferrin to that of FITC-labeled dextran (70 kDa) as a similar size control. The permeation ratio of transferrin was 2.5-fold higher than that of dextran (Fig. 5B) . Given that transferrin permeates into cells via its association with the transferrin receptor in the endocytic pathway, whereas dextran passively permeates through the intercellular gap, this result suggested that the assay system is functional. In a time course experiment, PV was shown to efficiently permeate through MBEC4 cells into the lower chamber (Fig. 5C) . However, this PV transport was delayed by the addition of transferrin (Fig. 5C ). Because transferrin is known to interact with the protease-like domain (PD2) of TfR1 (44, 45) , PV capsids and transferrin would compete for this TfR1 domain, which is in agreement with the result shown in Fig. 2C . To validate whether unmodified PV particles also require mTfR1 to permeate through MBEC4 cells, we constructed retroviral vector expressing shRNA against mTfR1 (sh-mTfR1). Stable transductants were obtained using appropriate antibiotics (Fig. 5D ). We confirmed knockdown of mTfR1 expression on these cells by flow cytometric analysis (Fig. 5E) . Using mTfR1 or control knockdown MBEC4 cells, we performed the Transwell BBB in vitro model assay. The number of permeated PVs was estimated by colony forming assay in AGMK cells. From the results, PV permeation was delayed in mTfR1 knockdown MBEC4 cells as compared with control MBEC4 cells (Fig. 5F ). These results confirmed the positive role of mTfR1 in PV permeation through brain capillary cells. Additionally, the results showed that PV retains its infectivity after transmission through MBEC4 cells.
Discussion
Given that PV permeates the brain as fast as cationized rat albumin with a high permeation rate in non-hPVR-Tg mice (16) , it is believed that PV can directly invade the CNS via BBB transmission in an hPVR-independent manner. In this study, we suggest a novel pathway where PV invades the CNS in an hPVR-independent manner and that mTfR1 is a key receptor on brain capillary endothelial cells, responsible for PV permeation of the CNS via the BBB. Transferrin receptor is known to be a crucial molecule for cellular homeostasis during oxygenation (26) . Because the CNS also requires active oxygenation and the antibody against the transferrin receptor stains brain capillary cells in the rat brain after intravenous administration (46, 47) , transferrin receptor is a plausible candidate for the receptor of PV permeation of the brain.
PV clearly interacted with mTfR1 proteins in vitro (Figs. 1 and 2) in this study, and we found that VP1 is responsible for this binding (Fig. 3B) . VP1 is also known to play a role in the interaction with hPVR/CD155. hPVR/CD155 inserts into the deep pocket "canyon" on the surface of the PV particle, which is composed of capsid proteins (43) . After the association between the canyon and hPVR/CD155, the uncoating process promptly occurs in the PV particle. For PV proliferation in the brain after BBB transport, PV needs to retain its infectivity after transcytosis. The in vitro BBB model assay showed that permeated materials contained intact infectious particles (Fig. 5F ). This result implies that PV permeates through brain capillary cells without loss of infectivity; a similar observation has been previously noted for the brain of hPVR-Tg and non-Tg mice (16) .
Our in vitro binding experiment showed that F-G, G-H, and H-I loops are the VP1 regions responsible for mTfR1 interaction (Fig. 4C) . The three-dimensional prediction analysis for PV particles showed that the G-H loop of VP1 faces the outer side and is located near the canyon, although the F-G and H-I loops of VP1 face the inside of the PV capsid. Considering this struc- tural analysis, G-H loop of VP1 is expected to be a probable candidate for mTfR1 binding. Further analysis by inserting a mutation at this loop on VP1 in PV particle or using the specific antibody against the identified loop of VP1 is an effective approach for understanding this binding mechanism. Homology between the sequence of TfR1 in mice and humans is 77%, and both proteins play a role in iron delivery. Considering this, it is possible that PV also interacts with human TfR1 as a mediator for BBB permeation.
The in vitro BBB model using MBEC4 cells showed that in vitro translated GST-Venus proteins fused with C-D, D-E, and E-F loops of VP1 permeate to a comparatively greater extent than other loops (Fig. 4D) . All of these loops face the outer side of the PV particle, as revealed by the three-dimensional prediction analysis. This result shows that the VP1 loops responsible for mTfR1 binding and for permeation into MBEC4 cells are clearly separated. However, co-incubation with transferrin or knocking down of mTfR1 inhibited the transcytosis of PV through MBEC4 cells (Fig. 5) ; therefore, we speculated that mTfR1 plays a role in attachment to the cell membrane, followed by PV permeation of the brain capillary endothelial cells. This also means that additional unidentified molecules would mediate this transcytosis. The expression of transferrin receptor is known to be ubiquitous, although the expression level is comparatively higher in brain capillary endothelial cells. If this PV permeation is a specific event in the BBB, the existence of additional molecules that are expressed only in brain capillary endothelial cells is plausible. Therefore, further studies are required to identify these molecules to better understand the BBB permeation mechanism.
It has been shown that in the case of hPVR-dependent endocytosis, the route for PV transmission into the brain is via peripheral MNs from the skeletal muscle (14) . However, PV can slowly transmit via MNs in non-hPVR Tg mice in vivo as well, although PV-containing endocytic vesicles were not observed in MNs cultured in vitro (15) . These observations indicate that PV also potentially moves to the CNS by an unknown, hPVRindependent endocytic pathway (16) . This discrepancy between in vitro and in vivo results may be explained by the decreased TfR1 expression in the extending neurites of MNs in culture (48) . It cannot be excluded that PV uses transferrin receptor as a positive mediator for transportation to the CNS from the skeletal muscles.
In this study, we showed that PV permeates mouse brain capillary endothelial cells through the BBB using the Transwell in vitro BBB model. Our results showed that mTfR1 is a positive mediator for BBB permeation of PV. To elucidate the complete mechanism for BBB permeation of PV, identification of the cellular counterpart for C-D, D-E, and E-F loops of VP1 is required. This study contributes to understanding the mechanism of viral transmission into the CNS, indicating its importance in the biology and pathogenesis of PV. Further, there is a growing recognition of the importance to develop CNS drug delivery systems. To this end, a BBB-permeable agent and/or a better understanding of delivering drug agents to the CNS is highly desired. Knowledge of the BBB permeation mechanism of PV will contribute to overcoming the challenge posed by the current inability to transport drugs to the CNS via the BBB.
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